Phage: Future Treatment Direction for inflammatory bowel disease Patients
DOI:
https://doi.org/10.54844/md.2023.0434Keywords:
Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, gut microbiota, phage, treatmentAbstract
Inflammatory bowel disease (IBD) is characterized by tissue damage resulting from uncontrolled innate and acquired immune responses. It is an autoimmune disease, including ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis (IC). The etiology of IBD is complex, and its clinical treatment faces significant challenges, necessitating urgent exploration of new treatment methods. Emerging evidence indicates that gut microbiota and IBD interact in the occurrence and development of diseases, emphasizing the importance of restoring gut microbiota imbalance. Phages have gained attention due to their potential to their potential to act on gut microbiota, offering advantages such as high efficiency, easy access, and ability to disrupt bacterial cell structures. Consequently, research into how phages interact with bacteria and their potential as a novel treatment for IBD has become a recent hotspot. Phages regulate intestinal inflammation by activating the immune system. Previous studies have observed an increase in the abundance of Caudovirales phages in IBD patients. Latest research reveals that special combinations of bacteriophages can effectively improve the symptoms of IBD model animals. This article reviews the interaction mechanism between phages and gut microbiota as well as the related research progress in IBD. The selection of articles retrieved on PubMed based on phage and Inflammatory bowel disease.
References
Wu KC, Liang J, Ran ZH, et al. Consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018). Chinese Journal of Digestion. 2018;38(5):292–311.
Goodman WA, Erkkila IP, Pizarro TT. Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(12):740–754. [PMID: 32901108 DOI: 10.1038/s41575–020–0354–0]
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66. [PMID: 33033392 DOI: 10.1038/s41575–020–00360-x]
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. [PMID: 31648971 DOI: 10.1016/S2468–1253(19)30333–4]
Bian X, Wu W, Yang L, et al . Administration of Akkermansia muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. Front Microbiol. 2019;10:2259. [PMID: 31632373 DOI: 10.3389/fmicb.2019.02259]
Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019;2019:7247238. [PMID: 31886308 DOI: 10.1155/2019/7247238]
Wu Y, Chen P. Role and therapeutic prospect of Intestinal microecology in inflammatory bowel disease. Medical Recapitulate. 2017;23(23):4688–93.
Esteban-Torres M, Ruiz L, Rossini V, Nally K, van Sinderen D. Intracellular glycogen accumulation by human gut commensals as a niche adaptation trait. Gut Microbes. 2023;15(1):2235067. [PMID: 37526383 DOI: 10.1080/19490976.2023.2235067]
Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638. [PMID: 15831718 DOI: 10.1126/science.1110591]
Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37(1):47-55. doi:10.1007/s00281-014-0454-4
Vieira-Silva S, Sabino J, Valles-Colomer M, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol. 2019;4(11):1826–1831. [PMID: 31209308 DOI: 10.1038/s41564–019–0483–9]
Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145(1):16-27.
Hooper LV. Bacterial contributions to mammalian gut development. Trends Microbiol. 2004;12(3):129–134. [PMID: 15001189 DOI: 10.1016/j.tim.2004.01.001]
Maronek M, Link R, Ambro L, Gardlik R. Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease. Cells. 2020;9(4):1013. [PMID: 32325706 DOI: 10.3390/cells9041013]
Zhang Y, Wang R. The human gut phageome: composition, development, and alterations in disease. Front Microbiol. 2023;14:1213625. [PMID: 37476672 DOI: 10.3389/fmicb.2023.1213625]
Wu Y, Huang X. Advances in the traetment of bacterial infections by phages [J]. Chinese Journal of Infection Control. 2021;20(2):186–90.
Ezzatpour S, Mondragon Portocarrero ADC, Cardelle-Cobas A, et al. The Human Gut Virome and Its Relationship with Nontransmissible Chronic Diseases. Nutrients. 2023;15(4):977. [PMID: 36839335 DOI: 10.3390/nu15040977]
Nir-Paz R, Kuijper EJ. Bacteriophage therapy in humans. Clin Microbiol Infect. 2023;29(6):679–681. [PMID: 36914071 DOI: 10.1016/j.cmi.2023.03.011]
Wang M, Shao Y, Wang C, et al. A review of the characteristics of mechanism and research progress of bacteriophage in the treatment of infectious diseases. Journal Of China Prescription Drug. 2022;20(6):154–157 .
Federici S, Kviatcovsky D, Valdés-Mas R, Elinav E. Microbiome-phage interactions in inflammatory bowel disease. Clin Microbiol Infect. 2023;29(6):682–688. [PMID: 36191844 DOI: 10.1016/j.cmi.2022.08.027]
Shuwen H, Kefeng D. Intestinal phages interact with bacteria and are involved in human diseases. Gut Microbes. 2022;14(1):2113717. [PMID: 36037202 DOI: 10.1080/19490976.2022.2113717]
Cepko LCS, Garling EE, Dinsdale MJ, et al. Myoviridae phage PDX kills enteroaggregative Escherichia coli without human microbiome dysbiosis. J Med Microbiol. 2020 Feb;69(2):309–323.
Borodovich T, Shkoporov AN, Ross RP, Hill C. Phage-mediated horizontal gene transfer and its implications for the human gut microbiome. Gastroenterol Rep (Oxf). 2022;1:0. [PMID: 35425613 DOI: 10.1093/gastro/goac012]
Chen J, Novick RP. Phage-mediated intergeneric transfer of toxin genes. Science. 2009;323(5910):139–141. [PMID: 19119236 DOI: 10.1126/science.1164783]
Das B, Bischerour J, Val ME, Barre FX. Molecular keys of the tropism of integration of the cholera toxin phage. Proc Natl Acad Sci U S A. 2010;107(9):4377–4382. [PMID: 20133778 DOI: 10.1073/pnas.0910212107]
Hsu BB, Gibson TE, Yeliseyev V, et al. Dynamic Modulation of the Gut Microbiota and Metabolome by Bacteriophages in a Mouse Model. Cell Host Microbe. 2019;25(6):803–814. [PMID: 31175044 DOI: 10.1016/j.chom.2019.05.001]
Seed KD, Faruque SM, Mekalanos JJ, Calderwood SB, Qadri F, Camilli A. Phase variable O antigen biosynthetic genes control expression of the major protective antigen and bacteriophage receptor in Vibrio cholerae O1. PLoS Pathog. 2012;8(9):e1002917. [PMID: 23028317 DOI: 10.1371/journal.ppat.1002917]
Ongenae V, Briegel A, Claessen D. Cell wall deficiency as an escape mechanism from phage infection. Open Biol. 2021;11(9):210199. [PMID: 34465216 DOI: 10.1098/rsob.210199]
Magadán AH, Dupuis MÈ, Villion M, Moineau S. Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system. PLoS One. 2012;7(7):e40913. [PMID: 22911717 DOI: 10.1371/journal.pone.0040913]
Liang G, Cobián-Güemes AG, Albenberg L, Bushman F. The gut virome in inflammatory bowel diseases. Curr Opin Virol. 2021;51:190–198. [PMID: 34763180 DOI: 10.1016/j.coviro.2021.10.005]
Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. Proc Natl Acad Sci U S A. 2016;113(37):10400–10405. [PMID: 27573828 DOI: 10.1073/pnas.1601060113]
Zuo T, Lu XJ, Zhang Y, et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019;68(7):1169–1179. [PMID: 30842211 DOI: 10.1136/gutjnl-2018–318131]
Norman JM, Handley SA, Baldridge MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015;160(3):447–460. [PMID: 25619688 DOI: 10.1016/j.cell.2015.01.002]
Clooney AG, Sutton TDS, Shkoporov AN, et al. Whole-Virome Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease. Cell Host Microbe. 2019;26(6):764–778. [PMID: 31757768 DOI: 10.1016/j.chom.2019.10.009]
Nishiyama H, Endo H, Blanc-Mathieu R, Ogata H. Ecological Structuring of Temperate Bacteriophages in the Inflammatory Bowel Disease-Affected Gut. Microorganisms. 2020;8(11):1663. [PMID: 33121006 DOI: 10.3390/microorganisms8111663]
Duerkop BA, Kleiner M, Paez-Espino D, et al. Murine colitis reveals a disease-associated bacteriophage community. Nat Microbiol. 2018;3(9):1023–1031. [PMID: 30038310 DOI: 10.1038/s41564–018–0210-y]
Gogokhia L, Round JL. Immune-bacteriophage interactions in inflammatory bowel diseases. Curr Opin Virol. 2021;49:30–35. [PMID: 34029992 DOI: 10.1016/j.coviro.2021.04.010]
Nguyen S, Baker K, Padman BS, et al. Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers. MBio. 2017;8(6):e01874–01817. [PMID: 29162715 DOI: 10.1128/mBio.01874–17]
Fatemeh Adiliaghdam, Hajera Amatullah, Sreehaas Digumarthi, et al. Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation. Sci Immunol. 2022;7(70):eabn6660. DOI: 10.1126/sciimmunol.abn6660]
Federici S, Kredo-Russo S, Valdés-Mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022;185(16):2879–2898. [PMID: 35931020 DOI: 10.1016/j.cell.2022.07.003]
Sinha A, Li Y, Mirzaei MK, et al. Transplantation of bacteriophages from ulcerative colitis patients shifts the gut bacteriome and exacerbates the severity of DSS colitis. Microbiome. 2022;10(1):105. [PMID: 35799219 DOI: 10.1186/s40168–022–01275–2]
Fatemeh Adiliaghdam, Hajera Amatullah, Sreehaas Digumarthi, et al. Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation. Sci Immunol. 2022;7(70):eabn6660. DOI: 10.1126/sciimmunol.abn6660]
Gogokhia L, Buhrke K, Bell R, et al. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell Host Microbe. 2019;25(2):285–299. [PMID: 30763538 DOI: 10.1016/j.chom.2019.01.008]
Taha OA, Connerton PL, Connerton IF, El-Shibiny A. Bacteriophage ZCKP1: A Potential Treatment for Klebsiella pneumoniae Isolated From Diabetic Foot Patients. Front Microbiol. 2018;9:2127. [PMID: 30254618 DOI: 10.3389/fmicb.2018.02127]
Sarker SA, Sultana S, Reuteler G, et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine. 2016;4:124–137. [PMID: 26981577 DOI: 10.1016/j.ebiom.2015.12.023]
Fuerte-Stone J, Mimee M. Host happy hour: Phage cocktail targets IBD-associated microbes. Cell Host Microbe. 2022;30(10):1352–1353. [PMID: 36228584 DOI: 10.1016/j.chom.2022.09.010]
Van Belleghem JD, Clement F, Merabishvili M, Lavigne R, Vaneechoutte M. Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep. 2017;7(1):8004. [PMID: 28808331 DOI: 10.1038/s41598–017–08336–9]
Titécat M, Rousseaux C, Dubuquoy C, et al. Safety and Efficacy of an AIEC-targeted Bacteriophage Cocktail in a Mice Colitis Model. J Crohns Colitis. 2022;16(10):1617–1627. [PMID: 35997152 DOI: 10.1093/ecco-jcc/jjac064]
Duan Y, Young R, Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2022;19(2):135–144. [PMID: 34782783 DOI: 10.1038/s41575–021–00536-z]
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Microbiota & Diseases
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
